Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.505 SEK | -2.70% |
|
+1.00% | +10.62% |
Jul. 01 | Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis | CI |
May. 22 | Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.62% | 17.35M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- ACTI Stock
- News Active Biotech AB
- Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops